GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosenic (XBRU:BIOS) » Definitions » Ending Cash Position

Biosenic (XBRU:BIOS) Ending Cash Position : €0.82 Mil (As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Biosenic Ending Cash Position?

Biosenic's Ending Cash Position for the quarter that ended in Jun. 2024 was €0.82 Mil.

Biosenic's quarterly Ending Cash Position declined from Jun. 2023 (€0.52 Mil) to Dec. 2023 (€0.12 Mil) but then increased from Dec. 2023 (€0.12 Mil) to Jun. 2024 (€0.82 Mil).

Biosenic's annual Ending Cash Position increased from Dec. 2021 (€0.76 Mil) to Dec. 2022 (€1.85 Mil) but then declined from Dec. 2022 (€1.85 Mil) to Dec. 2023 (€0.12 Mil).

Biosenic Ending Cash Position Historical Data

The historical data trend for Biosenic's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosenic Ending Cash Position Chart

Biosenic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.63 14.65 0.76 1.85 0.12

Biosenic Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 1.85 0.52 0.12 0.82

Biosenic Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Biosenic's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1.846+-1.729
=0.12

Biosenic's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.117+0.699
=0.82

Biosenic Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Biosenic's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosenic Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosenic (XBRU:BIOS) » Definitions » Ending Cash Position
Comparable Companies
XBRU:OXUR XBRU:CYAD XBRU:ALIMG OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN XBRU:UCB
Traded in Other Exchanges
0R55:UK BT1:Germany
Address
Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, BEL, 1435
Website
https://www.biosenic.com
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.